EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential

Die Li, Shiqi Hu, Jiarong Ye, Chaojie Zhai, Jipeng Liu, Zuao Wang, Xinchi Zhou, Leifeng Chen, Fan Zhou

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252212150 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Die Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, RNA-Binding Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Project of the Jiangxi Provincial Department of Science and Technology, Jiangxi Provincial High-level and Highly Skilled Leading Talents Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor resistance is one of the primary reasons for cancer treatment failure, significantly limiting the options and efficacy of cancer therapies. Therefore, overcoming resistance has become a critical factor in improving cancer treatment outcomes. IGF2BP2, as a reader of m6A methylation, plays a pivotal role in the post-transcriptional regulation of RNA through the methylation of m6A sites. It not only contributes to cancer initiation and progression but also plays a key role in tumor drug resistance. This review provides a comprehensive summary of the mechanisms by which IGF2BP2 contributes to therapy resistance, with the aim of improving the efficacy of chemotherapy in cancer treatment. Advancing research in this area is crucial for developing more effective therapies that could significantly improve the quality of life for cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmNeoplasmsRNA-Binding ProteinsHumansGene Expression Regulation, NeoplasticAnimalsAntineoplastic Agents

Stichwörter der Autor:innen

IGF2BP2RNA modificationscancerdrug resistancem6A modification

Substanzen

RNA-Binding ProteinsIGF2BP2 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200433, China.
  • Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Medical Center for Cardiovascular Diseases, Neurological Diseases and Tumors of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.

Förderung

  • National Natural Science Foundation of China
  • Project of the Jiangxi Provincial Department of Science and Technology
  • Jiangxi Provincial High-level and Highly Skilled Leading Talents Training Program
  • the Education Project of Jiangxi Provincial

Zitieren

APA

Li, D., Hu, S., Ye, J., Zhai, C., Liu, J., Wang, Z., Zhou, X., Chen, L., & Zhou, F. (2024). The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212150

Vancouver

Li D, Hu S, Ye J, Zhai C, Liu J, Wang Z, et al. The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212150

BibTeX
@article{Li2024,
  author = {Li, Die and Hu, Shiqi and Ye, Jiarong and Zhai, Chaojie and Liu, Jipeng and Wang, Zuao and Zhou, Xinchi and Chen, Leifeng and Zhou, Fan},
  title = {The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252212150}
}
Kostenlos starten →